The clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Type 1 Diabetes (Juvenile Diabetes)
- Mar 25, 2025: Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 ADA 85th Scientific Sessions
- Mar 19, 2025: Diamyd Medical Plans for GMP Certification in 2025
- Mar 18, 2025: FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes
- Mar 17, 2025: Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by Its Proprietary Nanoparticle Platform in Frontiers in Immunology
- Mar 17, 2025: Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg
- Mar 13, 2025: Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in April
- Mar 07, 2025: TIXiMED Announces Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes
- Mar 06, 2025: Adimune to Ship Final Drug Product Formulation of ADI-100 Ahead Planned Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome
- Feb 27, 2025: Tiximed Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, Its Investigational Disease-Modifying for Type 1 Diabetes
- Feb 25, 2025: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
- Feb 24, 2025: Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
- Feb 20, 2025: Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Mexico
- Jan 28, 2025: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Region, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Co
- Sanofi
- MannKind Corp
- Adocia SAS
- Medtronic Plc
- Pfizer Inc
- AstraZeneca Plc
- ProSciento Inc
- Lexicon Pharmaceuticals Inc
- Wockhardt Ltd
